INIT Stock Overview
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Initiator Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr8.94 |
| 52 Week High | kr12.20 |
| 52 Week Low | kr5.00 |
| Beta | 0.73 |
| 1 Month Change | -0.22% |
| 3 Month Change | 3.95% |
| 1 Year Change | 59.07% |
| 3 Year Change | 107.91% |
| 5 Year Change | n/a |
| Change since IPO | 54.14% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27
Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
May 20Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
Jan 06We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
Oct 26We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate
Jun 12Shareholder Returns
| INIT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.4% | -0.06% | 0.9% |
| 1Y | 59.1% | -5.3% | 10.3% |
Price Volatility
| INIT volatility | |
|---|---|
| INIT Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: INIT has not had significant price volatility in the past 3 months.
Volatility Over Time: INIT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 3 | Claus Olesen | www.initiatorpharma.com |
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor which is in Phase Ib clinical trials for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indication in severe neuropathic pain, and trigeminal neuralgia. The company also developing IP2017, a proprietary triple reuptake inhibitor of 5-HT, NA, and DA; and IP2016, a preclinical development for the treatment of depression.
Initiator Pharma A/S Fundamentals Summary
| INIT fundamental statistics | |
|---|---|
| Market cap | kr473.07m |
| Earnings (TTM) | -kr35.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.3x
P/E RatioIs INIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INIT income statement (TTM) | |
|---|---|
| Revenue | kr.0 |
| Cost of Revenue | kr.23.41m |
| Gross Profit | -kr.23.41m |
| Other Expenses | -kr.540.00k |
| Earnings | -kr.22.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 138.3% |
How did INIT perform over the long term?
See historical performance and comparison